Acarbose Tablets 25 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Acarbose Tablets 25 mg | Manufacturer
Product image for Acarbose Tablets 25 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Acarbose |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | USP / IP |
| Product Type | Tablet |
| Category | Antidiabetic Drugs |
| Subcategory | Alpha-Glucosidase Inhibitors |
| Active Ingredient | Acarbose |
| Strength | 25 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Antidiabetic Drugs - Alpha-Glucosidase Inhibitors |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Acarbose Tablets 25 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Monotherapy or adjunctive therapy to diet and exercise in patients with type 2 diabetes mellitus (T2DM). 2. Combination therapy with metformin, sulfonylureas, or insulin when single agents fail to achieve glycemic targets. 3. Prevention of type 2 diabetes in individuals diagnosed with impaired glucose tolerance (prediabetes). | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Acarbose Tablets 25 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Acarbose Tablets 25 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Acarbose Tablets 25 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Acarbose Tablets 25 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally immediately before meals or chewed with the very first mouthful of food. Recommended starting dosage: 25 mg or 50 mg once to thrice daily with main meals. Titrate upward at 4 to 8-week intervals based on 1-hour and 2-hour postprandial glucose and HbA1c levels, up to a maximum dose of 100 mg three times daily to minimize gastrointestinal discomfort. | ||||||||||||||||||||||||
| Side Effects | Very Common (>10%): Flatulence, abdominal distension, borborygmi (intestinal rumbling). Common (1-10%): Diarrhea, abdominal cramps, mild nausea. Uncommon to Rare (<1%): Transient asymptomatic hepatic transaminase elevation, allergic dermatitis, erythema, exanthema, ileus or subileus. | ||||||||||||||||||||||||
| Warnings and Precautions | Hypoglycemia Management: If hypoglycemia develops when taken concomitantly with a sulfonylurea or insulin, administer oral glucose (dextrose) directly. Table sugar (sucrose) is ineffective due to acarbose-mediated sucrase inhibition. Hepatic Monitoring: Monitor serum transaminases periodically during the first 6 to 12 months of therapy. Renal Impairment: Not recommended in severe renal failure (serum creatinine > 2.0 mg/dL or creatinine clearance < 25 mL/min). | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to acarbose or tablet excipients. 2. Inflammatory bowel disease (Crohn's disease, ulcerative colitis), severe intestinal ulceration, or chronic malabsorption syndromes. 3. Partial or complete intestinal obstruction, or conditions predisposing to bowel obstruction (e.g., Roemheld syndrome, large abdominal hernias). 4. Severe renal impairment (CrCl < 25 mL/min). 5. Diabetic ketoacidosis or diabetic hyperosmolar state. | ||||||||||||||||||||||||
| Drug Interactions | 1. Digestive Enzymes & Adsorbents: Intestinal adsorbents (charcoal) and amylase/pancreatin preparations diminish acarbose activity; avoid concurrent administration. 2. Sulfonylureas & Insulin: Potentiates hypoglycemic risk; downward dosage adjustment of insulin secretagogues may be required. 3. Digoxin: Acarbose reduces plasma bioavailability of digoxin; monitor serum digoxin levels. 4. Thiazide Diuretics & Corticosteroids: Antagonize glycemic control, requiring acarbose dose titration. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Acarbose Tablets 25 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Acarbose Tablets 25 mg? | The source specification is USP / IP; confirm the required standard before contracting. |
| What quality tests are applicable for Acarbose Tablets 25 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Acarbose Tablets 25 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Acarbose Tablets 25 mg? | Provide forecast volume, target market, strength and packaging requirements. |
Related Products












